Between January and July 2018, Russia imported 55 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms around 30% higher than that of the same period of 2018. The dynamics in physical terms are -2%, with 6.7 tons of APIs.

The dynamics of technical API import in monetary terms are +65%, while those of pharmacopoeial API import are +30%. The July results contributed to the total dynamics, with a 3 times increase of technical API import (0.41 bln RUB), which is the highest import volume since October 2015. In physical terms, the dynamics are negative for both technical and pharmacopoeial API import, with -8.1% and -1.6%, respectively.

Between January and July 2018, Russia imported API from 36 countries. Singapore is the only new country on the list. The only API imported from Singapore in 2018 was Enoxaparinum natrium, 5 kg / 15.6 bln RUB by Sanofi. Clexane is yet to be localized in Russia, it is in-bulk packaged on Pharmstandard-Ufavita facilities.

Among the top 20 pharmacopoeial APIs, Vildagliptinum has the highest dynamics in monetary terms, with a nearly 13 times increase. The product is imported by Novartis, while the production of Galvus and Galvus Met are yet to be localized in Russia. Atazanavirum has both the highest dynamics and import volume among the technical APIs, with an 81 times increase in monetary terms. It is mostly imported by Pharmasyntez, as well as Farmslavl and R-Pharm.

Dynamics of pharmacopoeial and technical API import to Russia (2015 – 2017, January – July 2018), bln RUB